Adverse drug events (ADEs) risk signal mining related to eculizumab based on the FARES database

IntroductionEculizumab is a C5 complement inhibitor approved by the FDA for the targeted treatment of four rare diseases, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and aquaporin-4 immunoglobulin G-positive optic neuromy...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	Xi-Feng Wang, Lu-Ri Bao, Ta-La Hu, Rui-Feng Xu, Wu-Niri Gao, Jing-Yuan Wang, Jian-Rong Zhao, Zhen-Li Fu, Shu-Fang Wang, Yan Meng
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	Frontiers Media S.A. 2025-01-01
Cyfres:	Frontiers in Pharmacology
Pynciau:	eculizumab FAERS adverse drug events adverse drug reaction monitoring ADRM
Mynediad Ar-lein:	https://www.frontiersin.org/articles/10.3389/fphar.2024.1440907/full
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!